Literature DB >> 9011752

Dopamine transporter (Dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease.

K A Harrington1, S J Augood, A E Kingsbury, O J Foster, P C Emson.   

Abstract

The cellular expression of DAT mRNA and VMAT2 mRNA was investigated in sections of the human post-mortem substantia nigra in control and Parkinson's disease tissue using in situ hybridisation techniques. Short synthetic oligodeoxynucleotides were used to detect these gene transcripts at the cellular level. In the control human nigra, high levels of expression were seen in all sub-divisions of the substantia nigra, especially within medial regions. By contrast, the level of expression of both DAT mRNA and VMAT2 mRNA was markedly reduced in Parkinson's disease; these reductions in hybridisation signal were associated with (i) a marked loss of dopamine-containing cells in the substantia nigra, and (ii) a reduction in both DAT and VMAT2 signal per cell in the remaining pigmented neurones. These disease-related decreases in the cellular abundance of both DAT and VMAT2 gene transcripts in the surviving cells of the parkinsonian nigra may reflect compensatory changes in catecholamine signalling or may be a consequence of neuronal dysfunction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9011752     DOI: 10.1016/0169-328x(95)00278-z

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  29 in total

Review 1.  The reward circuit: linking primate anatomy and human imaging.

Authors:  Suzanne N Haber; Brian Knutson
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

2.  Intranigral dopamine toxicity and alpha-synuclein response in rats.

Authors:  Cristina Gómez-Santos; Pol Giménez-Xavier; Isidre Ferrer; Santiago Ambrosio
Journal:  Neurochem Res       Date:  2006-06-28       Impact factor: 3.996

Review 3.  The bimodal mechanism of interaction between dopamine and mitochondria as reflected in Parkinson's disease and in schizophrenia.

Authors:  Dorit Ben-Shachar
Journal:  J Neural Transm (Vienna)       Date:  2019-12-17       Impact factor: 3.575

Review 4.  Dopamine: Functions, Signaling, and Association with Neurological Diseases.

Authors:  Marianne O Klein; Daniella S Battagello; Ariel R Cardoso; David N Hauser; Jackson C Bittencourt; Ricardo G Correa
Journal:  Cell Mol Neurobiol       Date:  2018-11-16       Impact factor: 5.046

5.  Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains.

Authors:  T J Counihan; J B Penney
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154

6.  Vesicular monoamine transporter 2 and dopamine transporter are molecular targets of Pitx3 in the ventral midbrain dopamine neurons.

Authors:  Dong-Youn Hwang; Sunghoi Hong; Joo-Won Jeong; Sangdun Choi; Hansoo Kim; Jangwoo Kim; Kwang-Soo Kim
Journal:  J Neurochem       Date:  2009-09-24       Impact factor: 5.372

Review 7.  Parkinson's disease: is the initial treatment established?

Authors:  J Eric Ahlskog
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

8.  hVMAT2: A Target of Individualized Medication for Parkinson's Disease.

Authors:  Nian Xiong; Nuomin Li; Eden Martin; Jinlong Yu; Jie Li; Jing Liu; David Yue-Wei Lee; Ole Isacson; Jeffery Vance; Hong Qing; Tao Wang; Zhicheng Lin
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

Review 9.  Manganese-Induced Parkinsonism Is Not Idiopathic Parkinson's Disease: Environmental and Genetic Evidence.

Authors:  Tomás R Guilarte; Kalynda K Gonzales
Journal:  Toxicol Sci       Date:  2015-08       Impact factor: 4.849

10.  Association of VMAT2 gene polymorphisms with alcohol dependence.

Authors:  Christoph Fehr; Daniel Sommerlad; Thomas Sander; Ion Anghelescu; Norbert Dahmen; Armin Szegedi; Christiana Mueller; Peter Zill; Michael Soyka; Ulrich W Preuss
Journal:  J Neural Transm (Vienna)       Date:  2013-03-17       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.